PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy

    公开(公告)号:US20230173112A1

    公开(公告)日:2023-06-08

    申请号:US18161395

    申请日:2023-01-30

    CPC classification number: A61K51/0497 A61P13/08 A61P35/00

    Abstract: Theranostic agents incorporating a chelating moiety that can chelate a radioactive metal isotope and a PSMA-targeting moiety are disclosed herein. The theranostic agents, which can be used to treat and/or detect cancers associated with increased PSMA expression, have the formula:





    and include complexes, anions or salts thereof. Ri includes a chelating moiety; a is 0 or 1; n is an integer from 12 to 21; and R2 includes a prostate specific membrane antigen (PSMA)-targeting moiety. Optionally, the chelating moiety is chelated to a metal atom, where the metal atom is a positron or single photon emitting metal isotope, or an alpha, beta, or Auger emitting metal isotope.

    PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy

    公开(公告)号:US20230302164A1

    公开(公告)日:2023-09-28

    申请号:US18303708

    申请日:2023-04-20

    CPC classification number: A61K51/0497 A61P13/08 A61P35/00

    Abstract: Theranostic agents incorporating a chelating moiety that can chelate a radioactive metal isotope and a PSMA-targeting moiety are disclosed herein. The theranostic agents, which can be used to treat and/or detect cancers associated with increased PSMA expression, have the formula:





    and include complexes, anions or salts thereof. R1 includes a chelating moiety; a is 0 or 1; n is an integer from 12 to 21; and R2 includes a prostate specific membrane antigen (PSMA)-targeting moiety. Optionally, the chelating moiety is chelated to a metal atom, where the metal atom is a positron or single photon emitting metal isotope, or an alpha, beta, or Auger emitting metal isotope.

Patent Agency Ranking